Pharmacogenomics of 3,4-Methylenedioxymethamphetamine (MDMA): A Narrative Review of the Literature.
Pharmaceutics August 20, 2024 Guillaume Drevin, Maria Pena-Martin, Aurélien Bauduin et al. 4 citations
Genetic factors influence individual responses to MDMA, which is being studied for treating PTSD and substance use disorders. The catechol-O-methyltransferase (COMT) Val158Met polymorphism has been linked to cognitive and cardiovascular effects, and polymorphisms in the serotonin-linked promoter region (5HTTLPR) have been associated with mood disorders. However, only a few associations have been found, and many genes involved in MDMA metabolism and targets remain poorly investigated. Large-scale controlled pharmacogenomics studies are needed to optimize therapeutic use and minimize risks.